Compare Novavax Inc (NVAX) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Koninklijke Philips NV — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Koninklijke Philips NV trades at $25.03 (market cap $24.84B). The key difference: Koninklijke Philips NV is far larger — about 14.8× Novavax Inc's market cap, and Koninklijke Philips NV pays a 4.01% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PHG | |
|---|---|---|
Market Cap | $1.68B | $24.84B |
Sector | Health | Health |
52-Week High | $11.19 | $32.91 |
52-Week Low | $6.22 | $25.02 |
Enterprise Value | $1.26B | $31.44B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
PHG trades at $25.29, down 2.32% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.57 versus $0.40 expected, continuing a trend of profitability after a turnaround from losses in prior years. Recent news highlights product launches in health technology and a $33.7 million award for AI-enabled stroke care (Business Wire, 2026-08-26).
The outlook is mixed: fundamentals show improving margins and cash flow, but technical indicators and a majority hold analyst rating suggest near-term caution. Key risks include competitive pressures and execution of growth initiatives, while institutional buying activity indicates underlying confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
